Advanced Therapies in Belgium’s Post

📖 An interesting report by Deloitte in collaboration with BioWin and MEDVIA. On top of our recent success stories within the ATMP field, our country needs more cross-region collaboration and investments to stay ahead of the curve. 👉 Read the full report: https://lnkd.in/e9-Umsc9

What is the Belgian recipe for an innovative ecosystem in advanced therapies? Read this interesting Paper from Deloitte, developed with input from BioWin and MEDVIA. It addresses the challenges in commercialising advanced therapies and highlights Belgium’s potential to become a biomanufacturing hub in Europe, thanks to its strong logistics, academic expertise, and infrastructure. 👉 Download the full report: https://lnkd.in/eKrAT5UP

"At the heart of Europe, Benelux is like a drop of ink spreading its influence internationally; an in-depth study conducted by KBC Securities placed Belgium as Europe’s leading country for biotech in 2024." - Marjoke Le Roy for BioVox Jan Wauters, our Science and Technology Counselor from Flanders Investment & Trade (FIT), recently discussed Flanders’ pivotal role as a knowledge hub within the Benelux life sciences ecosystem. Here are some key insights from the interview: 👉 Leadership in Biotech: Belgium leads Europe in biotech, driven by Flanders' dynamic life sciences sector. 👉Government Support: Strong backing from the government, including financial aid and favorable tax systems, fosters innovation. 👉Collaborative Ecosystem: Continuous dialogue between industry, academia, and government is crucial. #FlandersLifeSciences #Innovation #GlobalOpportunities #Flanders Read the full article: https://lnkd.in/etHPYi3a

We just caught up with Alex Meldrum, who attended DIA Europe in Brussels last week. This year's conference focused on sustainability, innovation, and collaboration — three pivotal pillars driving the future of healthcare.   With DIA Europe hosting such a wide range of thought-provoking discussions and insights, it’s impossible to cover them all.    Here's what Alex had to say about his key takeaways from the conference:   “As an experienced European regulatory professional, it was good to learn about credible multi-stakeholder co-operation and collaboration that acknowledges the scientific and societal challenges associated with medicines development. As a former healthcare professional, it was great to see the emphasis on patients as core-contributors.    It was refreshing to hear the regulators and payers acknowledge that change is constant, and not every change is associated with increased efficiencies and reducing barriers to patient access. But learnings are influencing the many planned changes facing everyone in the near future.   Any fears about AI being the key theme of DIA this year, were allayed by the observation that drug development has always been based on data analysis (so nothing is fundamentally new). While generative AI is now available to everyone, we must use this tool in the most responsible and ethical way. A “robot” should only be thought of as a junior colleague who aims to help but will inevitably make mistakes.   Thanks to DIA for a great program and to the colleagues and friends I was able to meet.”   Looking forward to the next one! #DIAEurope2024 #ndagroup #events #innovation #regulatoryaffairs

🎥 Missed the event? Watch the highlights! Held in cooperation with FTI Consulting EU, the launch of the "The Economic Lens: Understanding What Makes the EU Attractive for Life Sciences" report brought together top minds in investment, policy, and life sciences to discuss the EU’s strengths, challenges, and the future of the #PharmaceuticalSector. 💡 In case you couldn’t join, we’ve got you covered! Watch the short recap video of the insightful discussion. 💼 Topics: 🔹 How does Europe compare with the US, when attracting #investment in life sciences – what are Europe’s strengths & weaknesses? 🔹 How to improve #EUCompetitiveness for the pharmaceutical sector, also reflecting on the Draghi and Letta reports, the proposed #PharmaPackage and the future #EUAgenda? 🔹 How can the EU build a thriving pharmaceutical ecosystem, what are the challenges ahead, in particular for small and mid-sized companies? ✨ Highlights include: 💬 Keynote: MEP Stine Bosse, Vice-Chair, Subcommittee on Public Health (#SANT), European Parliament 🗣️ Insights from top industry leaders, policymakers, and investors including: 🔸 Florian Schmidt (DG SANTE - European Commission), 🔸 Kim Jørgensen (Permanent representation of the European Investment Bank (EIB)), 🔸 Raúl Martín-Ruiz (Ysios Capital), 🔸 Toon Digneffe (Takeda), and 🔸 Alexander Natz (EUCOPE - European Confederation of Pharmaceutical Entrepreneurs). 📈 At the start of the new European Commission's mandate, the conversation on #EUInnovation and #LifeSciences investment is more timely than ever. 🔗 Read the complete report here: https://lnkd.in/e46gFERR #LifeSciences #Innovation #EUCOPE #PharmaPackage #Investment

Great read if you are active in the 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗲𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺 🧬. Key takeaways are: ➡️ Rapid pace of scientific innovation drives broader utilization for advanced therapies (beyond rare diseases) and higher feasibility to adopt in clinical practice (reducing COGS to improve affordability). ➡️ Yet, an advanced therapy ecosystem with the right level of funding and maturity across the value chain (e.g., manufacturing, logistics, talent, etc.) is a must for patient access and outcomes (i.e., enabling quality and performance of advanced therapies at commercial scale). ➡️ Belgium has all the right ingredients to tackle the challenges in the supply chain and establish itself as the biomanufacturing gateway to Europe, building on specialized logistics, multi-disciplinary academic centers, access to biomanufacturing infrastructure, novel funding schemes and innovative healthcare system in the heart of Europe.

Probably nothing really new or that we don't already know, but it is still worth reading this report, which reflects the perspective of #LifeSciences investors on how to make the #EU more attractive for #LifeSciences and improve #EUCompetitiveness in the #PharmaceuticalSector

Some thoughts for the past year and look ahead to the New year!In 2024, I discovered that true regulatory leadership isn't just about expertise—it's about bringing people together across borders to solve complex challenges.When I joined ELIQUENT Life Sciences as co-CEO, I didn't just change jobs. I stepped into a global mission to reimagine how regulatory expertise can transform healthcare innovation. Our year wasn't defined by metrics, but by the connections we built and the barriers we helped organisations navigate.Our journey took us across three continents, from the innovative halls of BioJapan to the strategic discussions at RAPS Convergence and BIO-Europe. Each conference wasn't just an event—it was an opportunity to understand how regulatory intelligence can bridge complex market entry challenges.Three moments that crystallized our approach this year:1. At BioJapan 2024, walking through Pacifico Yokohama, I realized innovation happens when diverse perspectives converge. Our discussions around biologicals and digital health weren't just technical—they were about human potential.https://https://lnkd.in/etcByJCD. During RAPS Convergence, we dove deep into the evolving regulatory landscape. The message was clear: adaptability isn't just a skill, it's a strategic imperative for life sciences organizations.https://https://lnkd.in/eDsE_uBZ. At BIO-Europe, our conversations went beyond consulting—we explored how strategic regulatory guidance can transform complex challenges into opportunities for seamless market entry.https://https://lnkd.in/egVhpPpv we look toward 2025, our focus remains crystal clear: expanding global regulatory expertise, particularly in biologicals and biosimilars. The future of healthcare innovation will be written by those who can navigate complexity with clarity, empathy, and strategic insight.To our global network of clients, colleagues, and partners: your trust fuels our mission to make regulatory navigation not just a process, but a pathway to breakthrough innovation.#GlobalRegulatoryAffairs #ELIQUENTLifeSciences #BiotechNetworking #LifeScienceLeadership #LinkedInRewind #Coauthor #2024wrapped--Get your 2024 LinkedIn Rewind! Go to coauthor.studio 

Deloitte's latest insights on the future of Belgium's advanced therapy ecosystem are out! In our latest paper, we explore how rapid scientific advancements are expanding the use of advanced therapies beyond rare diseases, making them more accessible and affordable in clinical practice. However, scaling these innovations requires a mature and well-funded ecosystem that supports the entire value chain—from innovation in manufacturing and logistics to talent development. Belgium, with its strategic location, specialized infrastructure, academic excellence, and innovative healthcare system, has all the right ingredients to become Europe's biomanufacturing gateway. Discover more about Belgium's role in shaping the future of advanced therapies in our report! #AdvancedTherapies #HealthcareInnovation #Biomanufacturing

🔊 on. An important message from Dr. Moira Gilchrist, Chief Communications Officer. ⬇️ JOIN Dr. Gilchrist and our panel of experts at the upcoming Open Science event on November 14 at 4:00 p.m. CET by clicking ATTEND here 👉 https://lnkd.in/eQQ_DsaB Topics at the event ⬇️ ✅ Milestones from our leading heated tobacco product ✅ Scientific evidence ✅ Progress in Japan ✅ Science-based regulation ✅ Product innovation #OpenScience #CompanyTransformation #IndustryTransformation #ProductInnovation #ProductResearch